Bibliographic Details
| Title: |
1643P A phase II clinical trial of regorafenib (REGO) combined with BRAF-/MEK-inhibitors in advanced pretreated BRAFV600-mutant (mut) melanoma (RegoMel). |
| Authors: |
Dirven, I.1 (AUTHOR), Bertels, C.1 (AUTHOR), Vounckx, M.1 (AUTHOR), Kessels, J.I.1 (AUTHOR), Vanlaer, N.1 (AUTHOR), Von Kemp, B.A.2 (AUTHOR), Fasolino, G.3 (AUTHOR), Awada, G.1 (AUTHOR), Neyns, B.1 (AUTHOR) |
| Source: |
Annals of Oncology. 2025 Supplement 2, Vol. 36, pS975-S975. 1p. |
| Database: |
Academic Search Ultimate |
